<DOC>
	<DOCNO>NCT01013389</DOCNO>
	<brief_summary>The primary objective clinical trial evaluate success rate Actifuse ABX INFUSE achieve bone fusion . The secondary objective clinical trial ass clinical outcome measurement .</brief_summary>
	<brief_title>Actifuse ABX Versus INFUSE Posterolateral Instrumented Lumbar Fusion ( PLIF ) With Interbody Fusion</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Has degenerative disc disease lumbar spine indicate back pain discogenic/degenerative origin , without leg pain , one follow condition document plain Xrays , CT scan MRI scan : Modic change . High intensity change annulus . Loss disc height . Decreased hydration disc . Canal stenosis without spondylotic slip . Gross facet joint change require fusion treatment . Have document annular pathology mean . ( e.g. , discography ) . Has preoperative Oswestry Back Disability Score 30 . Aged 18 75 year skeletally mature time surgery . Has respond nonoperative treatment ( e.g. , bed rest , physical therapy , medication and/or spinal injection ) period six month . If childbearing potential , patient nonpregnant , nonnursing agree become pregnant one year follow surgery . Is willing able comply study plan able understand sign Patient Informed Consent Form . Has previous fail attempt fusion surgery involve level ( ) . Has diagnosis spinal infection tumour trauma . Requires surgery two ( 2 ) level . Has osteoporosis ( exclude osteopenia ) evidence plain Xrays , CT scan ( DEXA scan case doubt ) . Is pregnant . Is alcohol and/or drug abuser define currently undergo treatment alcohol and/or drug abuse . Has receive drug may interfere bone metabolism within two week prior plan surgery date ( e.g. , steroids methotrexate ) exclude routine perioperative , nonsteroidal antiinflammatory drug . Has history autoimmune disease . Has history exposure injectable collagen implant . Has history hypersensitivity protein pharmaceutical ( monoclonal antibody gamma globulin ) collagen . Has receive treatment investigational therapy ( device and/or pharmaceutical ) within 30 day prior surgery treatment plan 24 month follow surgery . Has receive previous exposure any/all BMPs either human animal extraction . Has history allergy bovine product history general anaphylaxis . Has history endocrine metabolic disorder know affect osteogenesis ( e.g. , Paget 's disease , renal oseodystrophy , EhlosDanlos syndrome osteogenesis imperfecta ) . Has disease would preclude accurate clinical evaluation ( e.g. , neuromuscular disease , etc. ) . Has primary diagnosis spinal disorder degenerative disc disease condition set `` inclusion '' involve level ( ) . Has condition require postoperative medication interfere fusion , steroid prolong use nonsteroidal antiinflammatory drug , exclude routine perioperative nonsteroidal antiinflammatory drug . This include low dose aspirin prophylactic anticoagulation . Has overt active bacterial infection , local systemic , and/or potential bacteremia . Has presence active malignancy prior history malignancy ( except basal cell carcinoma skin ) . Has document metal allergy intolerance titanium alloy cobaltchromemolybdenum alloy . Is , opinion Principal Investigator CoInvestigators , intellectually unable cooperate study . Has chronic acute renal and/or hepatic failure prior history renal hepatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>actifuse</keyword>
	<keyword>INFUSE</keyword>
	<keyword>InductOs</keyword>
	<keyword>DDD</keyword>
	<keyword>degenerative disk disease</keyword>
	<keyword>PLIF</keyword>
	<keyword>PITF</keyword>
	<keyword>PLF</keyword>
	<keyword>poterolateral lumber fusion</keyword>
	<keyword>Bone substitute</keyword>
	<keyword>bone graft</keyword>
	<keyword>synthetic bone substitute</keyword>
</DOC>